86. Pulmonary arterial hypertension Clinical trials / Disease details
Clinical trials : 1,181 / Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03554291 (ClinicalTrials.gov) | May 1, 2019 | 31/5/2018 | Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension | Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension | Pulmonary Arterial Hypertension;Right Heart Failure | Drug: Famotidine 20 MG;Other: Placebo | University of Washington | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 18 Years | 80 Years | All | 80 | Phase 2 | United States |